{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-042338","form_type":"8-K","ticker":"UNCY","cik":"0001766140","company_name":"Unicycive Therapeutics, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.965299+00:00","generated_at":"2026-06-02T02:32:05.586921+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Unicycive Q1 net loss $21.2M ($0.61/sh); OLC pivotal topline due Q2 2024","bullets":["Net loss $21.2M ($0.61/sh) vs $14.8M ($0.97) in Q1 2023; R&D expenses rose to $6.8M from $3.0M.","Cash $48.9M at March 31, 2024; funded operations expected into 2026.","Topline data from OLC pivotal trial in CKD on dialysis expected in Q2 2024.","UNI-494 Phase 1 MAD portion ongoing; FDA orphan drug designation for prevention of DGF in kidney transplant.","Completed $50M private placement with healthcare institutional investors."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-042338","json":"https://secwatch.observer/filing/0001213900-24-042338.json","markdown":"https://secwatch.observer/filing/0001213900-24-042338.md","text":"https://secwatch.observer/filing/0001213900-24-042338.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1766140/000121390024042338/0001213900-24-042338-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1766140/000121390024042338/ea0205889-8k_unicycive.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:32:05.586921+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"634e18a8943dbd27f7de42220c93591ffc740a90","claim":"Unicycive Therapeutics, Inc. reported the three months ended March 31, 2024 results: net income Net loss attributable to common stockholders for the three months ended March 31, 2024 was $21.2 million, or $0.61 per s, EPS $0.61 per share of common stock.","evidence_excerpt":"Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”) , a clinical-stage biotechnology company developing therapies for patients with kidney disease , today announced its financial results for the three months ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390024042338/0001213900-24-042338-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Net income","value":"Net loss attributable to common stockholders for the three months ended March 31, 2024 was $21.2 million, or $0.61 per s"},{"label":"EPS","value":"$0.61 per share of common stock"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}